Pathology and new insights in thyroid neoplasms in the 2022 WHO classification

被引:9
|
作者
Lebrun, Laetitia [1 ]
Salmon, Isabelle [1 ,2 ,3 ]
机构
[1] Univ Libre Bruxelles ULB, Erasme Univ Hosp, Hop Univ Bruxelles HUB, CUB Hop Erasme,Dept Pathol, Brussels, Belgium
[2] ULB, Ctr Microscopy & Mol Imaging CMMI, DIAPath, Gosselies, Belgium
[3] Univ Libre Bruxelles ULB, Erasme Univ Hosp HUB, Dept Pathol, Rue Meylemeersch 90, B-1070 Brussels, Belgium
关键词
Bethesda system; fine needle aspiration; molecular testing; screening; thyroid cancer; WHO classification; TERT PROMOTER MUTATIONS; ENCAPSULATED FOLLICULAR VARIANT; INTEROBSERVER VARIABILITY; ASSOCIATION GUIDELINES; GENETIC ALTERATIONS; VASCULAR INVASION; TASK-FORCE; CARCINOMA; CANCER; NODULES;
D O I
10.1097/CCO.0000000000001012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of reviewThe assessment of thyroid nodules is a common clinical problem, linked to the high incidence of thyroid nodules in the population and the low incidence of aggressive thyroid carcinoma. The screening is therefore one of the strengths of our patient care. Recently, the 2023 Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and 2022 WHO classification of thyroid neoplasms have been released based on the definition of new entities and the growing impact of molecular testing. The aim of this review is to analyze how these upgrades can help us in the daily routine practice diagnosis of thyroid cancer.Recent findingsOur review is focused on the most frequent thyroid tumors derived from thyroid follicular cell. Fine needle aspiration (FNA) is the gold standard for the screening of thyroid nodules with very high levels of sensitivity and specificity. These sensitivity and specificity are improved by molecular testing, which refines the risk of malignancy. The 2023 TBSRTC integrates molecular data and the upgrades integrated in the 2022 WHO classification such as the 'low-risk neoplasms' and the 'high-grade follicular-cells derived carcinoma'. The morphological examination remains crucial since the capsular and/or vascular invasion are key features of malignancy in the follicular thyroid neoplasms. Low-risk neoplasms represent a clinical challenge since no specific guidelines are available. Challenges remain regarding oncocytic thyroid lesions, which are not associated with specific diagnostic molecular biomarkers. Molecular testing can help not only in deciphering the prognosis but also in the targeted therapeutic strategy.SummaryWhile molecular testing has succeeded to substantially improve the pre and postoperative diagnosis and risk stratification of thyroid tumors, the morphological examination is still central in the daily routine diagnosis of thyroid pathology. Future is the integrated diagnosis of clinical, morphological, molecular and epigenetic features with the help of artificial intelligence algorithms.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 50 条
  • [31] 2016 WHO Classification updateWhat's new in lymphoid neoplasms
    Hsi, E. D.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 : 14 - 22
  • [32] Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms
    Kloeppel, Guenter
    ENDOCRINE-RELATED CANCER, 2011, 18 : S1 - S16
  • [33] New WHO classification 2022: urinary bladder cancer
    Gaisa, Nadine Therese
    Hartmann, Arndt
    Knuechel-Clarke, Ruth
    PATHOLOGIE, 2023, 44 (02): : 139 - 148
  • [34] The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms
    Khanna, Vishesh
    Lu, Rong
    Kumar, Jyoti
    Molina, Alfonso
    Stehr, Henning
    Spiteri, Elizabeth
    Spinner, Michael
    Silva, Oscar
    Fernandez-Pol, Sebastian
    Tan, Brent
    Greenberg, Peter L.
    LEUKEMIA RESEARCH, 2024, 136
  • [35] The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates
    Goswami, Parth R.
    Singh, Gyanendra
    Patel, Tarang
    Dave, Rushang
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [36] The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
    K. Nachtkamp
    C. Strupp
    M. Vukelja
    A. Kasprzak
    D. Haase
    C. Ganster
    B. Hildebrandt
    B. Betz
    A. Giagounidis
    C. Aul
    S. Blum
    W. K. Hofmann
    M. Pfeilstöcker
    P. Valent
    M. Lübbert
    M. Seidl
    M. Rudelius
    R. Stauder
    O. Krieger
    K. S. Götze
    J. Bobak
    A. Kündgen
    F. Schulz
    S. Dietrich
    G. Kobbe
    N. Gattermann
    U. Germing
    Leukemia, 2024, 38 : 442 - 445
  • [37] The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
    Nachtkamp, K.
    Strupp, C.
    Vukelja, M.
    Kasprzak, A.
    Haase, D.
    Ganster, C.
    Hildebrandt, B.
    Betz, B.
    Giagounidis, A.
    Aul, C.
    Blum, S.
    Hofmann, W. K.
    Pfeilstoecker, M.
    Valent, P.
    Luebbert, M.
    Seidl, M.
    Rudelius, M.
    Stauder, R.
    Krieger, O.
    Goetze, K. S.
    Bobak, J.
    Kuendgen, A.
    Schulz, F.
    Dietrich, S.
    Kobbe, G.
    Gattermann, N.
    Germing, U.
    LEUKEMIA, 2024, 38 (02) : 386 - 388
  • [38] Controversies in Thyroid Pathology: The Diagnosis of Follicular Neoplasms
    Stefano Serra
    Sylvia L. Asa
    Endocrine Pathology, 2008, 19 : 156 - 165
  • [39] Controversies in thyroid pathology: The diagnosis of follicular neoplasms
    Serra, Stefano
    Asa, Sylvia L.
    ENDOCRINE PATHOLOGY, 2008, 19 (03) : 156 - 165
  • [40] NEOPLASMS OF THE THYROID - CLASSIFICATION, MORPHOLOGY, AND TREATMENT
    HAZARD, JB
    CRILE, G
    DINSMORE, RS
    HAWK, WA
    KENYON, R
    ARCHIVES OF PATHOLOGY, 1955, 59 (04): : 502 - 513